Alzheimer’s

First Opinion By Jason Karlawish

If the FDA approves Biogen’s Alzheimer’s treatment, I won’t prescribe it

First Opinion By Jim Taylor

Medicare: Cover amyloid PET scans and stop keeping people with dementia in the dark

Biotech By Matthew Herper and Adam Feuerstein

Eli Lilly releases detailed results on Alzheimer’s drug, as data divide researchers

Biotech By Damian Garde

What to look for in Lilly’s eagerly awaited Alzheimer’s data

Aducanumab study participant Alzheimer's

Biotech By Damian Garde and Adam Feuerstein

How a scientific journal’s ‘grotesque overreaction’ inflamed the contentious debate over Biogen’s Alzheimer’s drug

Biotech By Matthew Herper, Adam Feuerstein and Damian Garde

Expert panel votes down Biogen’s Alzheimer’s drug, and rebukes the FDA in the process

Biotech By Damian Garde and Adam Feuerstein

Inside the tense, high-stakes meeting on Biogen’s Alzheimer’s treatment

Pharmalot By Ed Silverman

Most doctors view the Biogen Alzheimer’s drug favorably after reading briefing documents, survey finds

Biotech By Damian Garde and Adam Feuerstein

FDA scientists appear to offer major endorsement of Biogen’s controversial Alzheimer’s treatment

Biotech By Adam Feuerstein and Damian Garde

Your guide on how to prepare for a historic FDA panel meeting on Alzheimer’s

Biotech By Adam Feuerstein

A pivotal FDA meeting on Biogen’s Alzheimer’s treatment is near. Here’s what you need to know

Biotech By Adam Feuerstein

The FDA accepted Biogen’s Alzheimer’s drug submission. Next up, a highly anticipated outside expert review

Biotech By Damian Garde

Two more failed Alzheimer’s drugs sharpen focus on Biogen’s chances for aducanumab

Biotech By Jonathan Saltzman — Boston Globe

Startup Arkuda targets rapidly advancing, rare form of dementia

First Opinion By Dennis J. Selkoe

Biogen’s good news on aducanumab could ‘open the floodgates’ for Alzheimer’s drugs

In the Lab By Sharon Begley

New prize offers $2 million for finding key to Alzheimer’s in past research

Pharma By Sharon Begley

That pathetic Alzheimer’s pipeline? It’s even worse than you think

Pharmalot By Ed Silverman

Pharmalittle: Biogen argues investors overreacted; AstraZeneca wins a key immunotherapy approval

Adam's Take By Adam Feuerstein

In biotech, it pays to be bullish on Alzheimer’s trials, even when facts stand in the way

Alzheimer's brain illustration - Loss of connection between cells

Pharmalot By Ed Silverman

FDA is offering a new approach for developing Alzheimer’s drugs. What could that mean?

Biotech By Sharon Begley

In small Alzheimer’s study, hints of modest benefit from unusual drug

Pharmalot By Ed Silverman

Pharmalot, Pharmalittle: Former compounder told staff to stop ‘fudging’ after meningitis outbreak

Pharmalot By Ed Silverman

Lilly cuts 200 R&D jobs, but insists an Alzheimer’s failure is not the cause

Signal Podcast By Luke Timmerman and Meg Tirrell

Listen: Episode 19: From poop transplants to pill politics, here’s the year in ‘Signal’

Pharmalot By Ed Silverman

Most Read

Eli Lilly says drug slowed Alzheimer’s decline in preliminary study

Watch: Genetic tests promised to help me achieve peak fitness. What I got was a fiasco

Hospitalized adults need their caregivers — they aren’t visitors

Fans ‘didn’t care if he messed up’: Glen Campbell’s doctor discusses his struggle with Alzheimer’s

Peter Walter just won the Breakthrough Prize. His work? Trying to heal human brains

Why Nestlé — yes, that Nestlé — is acting a lot like a drug company

Athletes are keeping their distance from a genetic test for concussion risks

An FDA adviser on why his panel took a skeptical view on Biogen’s Alzheimer’s drug

All Coverage

If the FDA approves Biogen’s Alzheimer’s treatment, I won’t prescribe it

Medicare: Cover amyloid PET scans and stop keeping people with dementia in the dark

Eli Lilly releases detailed results on Alzheimer’s drug, as data divide researchers

What to look for in Lilly’s eagerly awaited Alzheimer’s data

How a scientific journal’s ‘grotesque overreaction’ inflamed the contentious debate over Biogen’s Alzheimer’s drug

Expert panel votes down Biogen’s Alzheimer’s drug, and rebukes the FDA in the process

Inside the tense, high-stakes meeting on Biogen’s Alzheimer’s treatment

Most doctors view the Biogen Alzheimer’s drug favorably after reading briefing documents, survey finds

FDA scientists appear to offer major endorsement of Biogen’s controversial Alzheimer’s treatment

Your guide on how to prepare for a historic FDA panel meeting on Alzheimer’s

A pivotal FDA meeting on Biogen’s Alzheimer’s treatment is near. Here’s what you need to know

The FDA accepted Biogen’s Alzheimer’s drug submission. Next up, a highly anticipated outside expert review

Two more failed Alzheimer’s drugs sharpen focus on Biogen’s chances for aducanumab

Startup Arkuda targets rapidly advancing, rare form of dementia

Biogen’s good news on aducanumab could ‘open the floodgates’ for Alzheimer’s drugs

New prize offers $2 million for finding key to Alzheimer’s in past research

That pathetic Alzheimer’s pipeline? It’s even worse than you think

Pharmalittle: Biogen argues investors overreacted; AstraZeneca wins a key immunotherapy approval

In biotech, it pays to be bullish on Alzheimer’s trials, even when facts stand in the way

FDA is offering a new approach for developing Alzheimer’s drugs. What could that mean?

In small Alzheimer’s study, hints of modest benefit from unusual drug

Pharmalot, Pharmalittle: Former compounder told staff to stop ‘fudging’ after meningitis outbreak

Lilly cuts 200 R&D jobs, but insists an Alzheimer’s failure is not the cause

Listen: Episode 19: From poop transplants to pill politics, here’s the year in ‘Signal’

Pharmalot, Pharmalittle: Handful of doctors responsible for high levels of fentanyl prescriptions